Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative Review

Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 2017;390(10100):1211–59.

Article  Google Scholar 

Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace. 2013;15(4):486–93.

Article  PubMed  Google Scholar 

Wilkinson C, Clegg A, Todd O, Rockwood K, Yadegarfar ME, Gale CP, et al. Atrial fibrillation and oral anticoagulation in older people with frailty: a nationwide primary care electronic health records cohort study. Age Ageing. 2021;50(3):772–9.

Article  PubMed  Google Scholar 

Laupacis A, et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154(13):1449–57.

Article  Google Scholar 

Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67.

Article  PubMed  Google Scholar 

Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151(5):297–305.

Article  PubMed  PubMed Central  Google Scholar 

Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. EP Europace. 2021;23(10):1612–76.

Article  Google Scholar 

Granger CB, Alexander JH, Mcmurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.

Article  CAS  PubMed  Google Scholar 

Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.

Article  CAS  PubMed  Google Scholar 

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.

Article  CAS  PubMed  Google Scholar 

Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.

Article  CAS  PubMed  Google Scholar 

Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy. Chest. 2012;141(2):e44S-e88S.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Witt DM, Clark NP, Kaatz S, Schnurr T, Ansell JE. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):187–205.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Groot JR, Weiss TW, Kelly P, Monteiro P, Deharo JC, De Asmundis C, et al. Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study. Eur Heart J Cardiovasc Pharmacother. 2021;7(FI1):f30–9.

Article  PubMed  Google Scholar 

Proietti M, Romanazzi I, Romiti GF, Farcomeni A, Lip GYH. Real-world use of apixaban for stroke prevention in atrial fibrillation. Stroke. 2018;49(1):98–106.

Article  CAS  PubMed  Google Scholar 

Ibáñez L, Sabaté M, Vidal X, Ballarin E, Rottenkolber M, Schmiedl S, et al. Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008–2015): a cross-national drug utilization study. Br J Clin Pharmacol. 2019;85(11):2524–39.

Article  PubMed  PubMed Central  Google Scholar 

Hias J, Van der Linden L, Walgraeve K, Gijsen M, Mian P, Koch BCP, et al. Pharmacokinetics of 2 oral paracetamol formulations in hospitalized octogenarians. Br J Clin Pharmacol. 2021;88:1020–30.

Article  PubMed  Google Scholar 

Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics—2009 update. Circulation. 2009;119(3):e21–181.

PubMed  Google Scholar 

Eurostat. Ageing Europe: Looking at the lives of older people in the EU. Luxembourg: Publications Office of the European Union. 2019.

Bramer WM, Giustini D, De Jonge GB, Holland L, Bekhuis T. De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc. 2016;104(3):240–3.

Article  PubMed  PubMed Central  Google Scholar 

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5:1.

Article  Google Scholar 

Bendayan M, Mardigyan V, Williamson D, Chen-Tournoux A, Eintracht S, Rudski L, et al. Muscle mass and direct oral anticoagulant activity in older adults with atrial fibrillation. J Am Geriatr Soc. 2021;69(4):1012–8.

Article  PubMed  Google Scholar 

Bernier M, Lancrerot SL, Rocher F, Van-Obberghen EK, Olivier P, Lavrut T, et al. Major bleeding events in octagenarians associated with drug interactions between dabigatran and P-gp inhibitors. J Geriatr Cardiol. 2019;16(11):806–11.

CAS  PubMed  PubMed Central  Google Scholar 

Bhagirath VC, Chan N, Hirsh J, Ginsberg J, de Vries TAC, Eikelboom J. Plasma apixaban levels in patients treated off label with the lower dose. J Am Coll Cardiol. 2020;76(24):2906–7.

Article  CAS  PubMed  Google Scholar 

Chaussade E, Hanon O, Boully C, Labourée F, Caillard L, Gerotziafas G, et al. Real-life peak and trough dabigatran plasma measurements over time in hospitalized geriatric patients with atrial fibrillation. J Nutr Health Aging. 2018;22(1):165–73.

Article  CAS  PubMed  Google Scholar 

Comans AL, Sennesael AL, Bihin B, Regnier M, Mullier F, de Saint-Hubert M. Inappropriate low dosing of direct oral anticoagulants in older patients with non-valvular atrial fibrillation: impact on plasma drug levels. Thromb Res. 2021;201:139–42.

Article  CAS  PubMed  Google Scholar 

Gendron N, Chocron R, Billoir P, Brunier J, Camoin-Jau L, Tuffigo M, et al. Dabigatran level before reversal can predict hemostatic effectiveness of idarucizumab in a real-world setting. Front Med. 2020;2020:7.

Google Scholar 

Gommans E, Grouls RJE, Kerkhof D, Houterman S, Simmers T, Van Der Linden C. Dabigatran trough concentrations in very elderly patients. Eur J Hosp Pharm. 2021;28(4):231–3.

Article  PubMed  Google Scholar 

Gulilat M, Keller D, Linton B, Pananos AD, Lizotte D, Dresser GK, et al. Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. J Thromb Thrombol. 2020;49(2):294–303.

Article  Google Scholar 

Ikeda K, Tachibana H. Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation. J Arrhythm. 2016;32(1):42–50.

Article  PubMed  Google Scholar 

Kampouraki E, Avery P, Biss T, Wynne H, Kamali F. Assessment of exposure to direct oral anticoagulants in elderly hospitalised patients. Br J Haematol. 2021;195(5):790–801.

Article  CAS  PubMed  Google Scholar 

Kryukov AV, Sychev DA, Andreev DA, Ryzhikova KA, Grishina EA, Ryabova AV, et al. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmacogenom Personal Med. 2018;11:43–9.

Article  CAS  Google Scholar 

Lin SY, Kuo CH, Huang TM, Peng YF, Huang CF, Tang SC, et al. Impact of different renal function equations on direct oral anticoagulant concentrations. Sci Rep. 2021;11(1):23833.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin SY, Kuo CH, Yeh SJ, Tsai LK, Liu YB, Huang CF, et al. Real-world rivaroxaban and apixaban levels in asian patients with atrial fibrillation. Clin Pharmacol Ther. 2020;107(1):278–86.

Article  CAS  PubMed  Google Scholar 

Mavri A, Vene N, Božič-Mijovski M, Miklič M, Söderblom L, Pohanka A, et al. Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation. Sci Rep. 2021;11(1):13908.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nissan R, Spectre G, Hershkovitz A, Green H, Shimony S, Cooper L, et al. Apixaban levels in octogenarian patients with non-valvular atrial fibrillation. Drugs Aging. 2019;36(2):165–77.

Article  CAS  PubMed  Google Scholar 

Okata T, Toyoda K, Okamoto A, Miyata T, Nagatsuka K, Minematsu K. Anticoagulation intensity of rivaroxaban for stroke patients at a special low dosage in Japan. PLoS ONE. 2014;9:11.

Article  Google Scholar 

Osanai H, Ajioka M, Masutomi T, Kuwayama T, Ishihama S, Sakamato Y, et al. Measurement of anti-factor xa activity in patients on apixaban for non-valvular atrial fibrillation. Circ J. 2015;79(12):2584–90.

Article  CAS  PubMed  Google Scholar 

Perlman A, Goldstein R, Choshen Cohen L, Hirsh-Raccah B, Hakimian D, Matok I, et al. Effect of enzyme-inducing antiseizure medications on the risk of sub-therapeutic concentrations of direct oral anticoagulants: a retrospective cohort study. CNS Drugs. 2021;35(3):305–16.

Article 

留言 (0)

沒有登入
gif